| Literature DB >> 20490260 |
Joanna Wiecek1, Dimitra Kovala-Demertzi, Zbigniew Ciunik, Joanna Wietrzyk, Maria Zervou, Mavroudis A Demertzis.
Abstract
The novel diphenyltin(IV) compound [Ph(2)(HyFoSc)Sn] (2), where H(2)HyFoSc (1) is 3-hydroxy-2-formylpyridine semicarbazone, was prepared and characterized by vibrational and NMR ((1)H, (13)C) spectroscopy. The structure of [Ph(2)(HyFoSc)Sn] was confirmed by single-crystal X-ray crystallography. The doubly deprotonated ligand is coordinated to the tin atom through the enolic-oxygen, the azomethine-nitrogen, and phenolic-oxygen, and so acts as an anionic tridentate ligand with the ONO donors. Two carbon atoms complete the fivefold coordination at the tin(IV) center. Intermolecular hydrogen bonding, C-H --> pi, and pi --> pi interactions combine to stabilize the crystal structure. Compounds 1 and 2 have been evaluated for antiproliferative activity in vitro against the cells of three human tumor cell lines: MCF-7 (human breast cancer cell line), T24 (bladder cancer cell line), A549 (nonsmall cell lung carcinoma), and a mouse fibroblast L-929 cancer cell line.Entities:
Year: 2010 PMID: 20490260 PMCID: PMC2869176 DOI: 10.1155/2010/718606
Source DB: PubMed Journal: Bioinorg Chem Appl Impact factor: 7.778
X-ray crystal data and structure refinement for 2.
| Empirical formula | C19H16N4O2Sn |
| Formula weight | 451.05 |
| Temperature (K) | 100(2) |
| Crystal system | Monoclinic |
| Space group |
|
| Crystal size (mm) | 0.17 × 0.20 × 0.23 |
|
| 10.5498(6) |
|
| 12.5794(7) |
|
| 13.9477(8) |
|
| 103.594(5) |
| Volume (Ǻ3) | 1799.2(2) |
|
| 4 |
|
| 1.665 |
| Absorption coefficient (mm−1) | 1.441 |
|
| 3.0–36.6 |
| Reflections collected | 29597 |
| Independent reflections ( | 8324 (0.056) |
| Data/parameters | 8324/243 |
| Goodness-of-Fit ( | 0.857 |
| Final | 0.037 |
|
| 0.062 |
| Maximum and minimum residuals (e·Ǻ−3) | 1.03/−0.74 |
Scheme 1The reaction scheme for synthesis of 1 and 2.
Figure 1Molecular structure of the diorganotin complex 2. Thermal ellipsoids are drawn at the 40% probability level.
Selected bond lengths (Å) and angles (°) for complex 2.
| Sn(1)–O(1) | 2.073 (2) | O(1)–Sn(1)–O(2) | 156.78(6) |
| Sn(1)–O(2) | 2.152(2) | O(1)–Sn(1)–N(1) | 84.71(6) |
| Sn(1)–N(1) | 2.166(2) | O(1)–Sn(1)–C(8) | 98.51(7) |
| Sn(1)–C(8) | 2.115(2) | O(1)–Sn(1)–C(14) | 95.64(7) |
| Sn(1)–C(14) | 2.121(2) | O(2)–Sn(1)–N(1) | 73.14(6) |
| O(1)–C(1) | 1.326(2) | O(2)–Sn(1)–C(8) | 95.84(7) |
| O(2)–C(4) | 1.297(2) | O(2)–Sn(1)–C(14) | 91.13(7) |
| N(1)–N(2) | 1.388(2) | N(1)–Sn(1)–C(8) | 110.80(7) |
| N(1)–C(3) | 1.298(3) | N(1)–Sn(1)–C(14) | 123.88(7) |
| N(2)–C(4) | 1.329(3) | C(8)–Sn(1)–C(14) | 124.44(8) |
| N(3)–C(4) | 1.338(3) | Sn(1)–O(1)–C(1) | 132.5(2) |
| N(4)–C(2) | 1.361(3) | Sn(1)–O(2)–C4 | 113.6(2) |
| N(4)–C(7) | 1.330(3) | Sn(1)–N(1)–N(2) | 116.2(2) |
Geometric parameters for hydrogen bonds and for C–H—π and π ⋯ π interactions in 2.
| D | H | A | H ⋯ A | D ⋯ A |
|---|---|---|---|---|
| N(3) –H(3A) ⋯ N(4)(i) | 2.29(2) | 3.070(3) | 175(3) | |
| N(3) –H(3B) ⋯ O(2)(ii) | 2.07(3) | 2.925(2) | 183(4) | |
| C(3) –H(3) ⋯ N(2)(i) | 2.34(2) | 3.280(3) | 170(3) | |
| C(19) –H(19) ⋯ O(2) | 2.51(2) | 3.087(3) | 119 | |
| C–H(I)→Cg(J)(a) | H–Cg | C–Cg | ∠C–H–Cg | |
| C(7) –H(7)→Cg(5)(iii) | 2.76 | 3.619(2) | 151 | |
| C(12) –H(12)→Cg(5)(iv) | 2.86 | 3.722(3) | 152 | |
| Cg(I)→Cg(J)(a) | Cg–Cg(b) |
| CgI–Perp(d) | CgJ–Perp(e) |
| Cg(3)→Cg(4)(v) | 3.824(2) | 10.55 | 3.7122(8) | 3.759(2) |
| Cg(4)→Cg(3)(iv) | 3.823(2) | 10.55 | 3.759(2) | 3.7121(8) |
(a)Where Cg(3), Cg(4), and Cg(5) are referred to the centroids N(4)C(1)C(2)C(5)C(6)C(7), C(8)–C(14), and C(14)–C(19); (b)Cg–Cg is the distance between ring centroids; symmetry transformations, (i) 2 − x, 1 − y, −z; (ii) 1 − x, 1 − y, −z; (iii) 1 + x, y, z; (iv) −1/2 + x, 1/2 − y, −1/2 + z; (v) 1/2 + x, 1/2 − y, 1/2 + z; (c)Where β is the angle Cg(I)→Cg(J) or Cg(i)→Me vector and normal to plane I (°); (d)CgI–Perp is the perpendicular distance of Cg(I) on ring J; (e)CgJ–Perp is the perpendicular distance of Cg(J) on ring I.
Figure 2Arrangement of the intermolecular hydrogen bonds in 2. Thermal ellipsoids are drawn at the 40% probability level.
Figure 31H NMR (a) and 13C NMR (b) spectrum of the ligand (1).
Figure 41H NMR (a) and 13C NMR (b) spectrum of the complex (2).
The antiproliferative activity in vitro of H2HyFoSc and its organotin complex 2 (expressed as ID50 (μM)) against MCF-7, T-24, A-549, and L-929 cancer cell lines.
| Compounds | L-929 | A-549 | T-24 | MCF-7 |
|---|---|---|---|---|
| [H2HyFoSc] ( | n.a | 175.0 | n.a. | 164.0 |
| [Ph2(HyFoSc)Sn] ( | 1.19 | 0.086 | n.a. | 8.65 |
| [Ph2SnO] | 10.73 | 47.10 | n.a | 3.46 |
| Cisplatin | 0.69 | 1.53 | 41.7 | 8.00 |